We’re gathering the facts and working with NewLife Pharmacy to understand whether any Fifty 410 patients may be affected.
Confirmed that your medication is included? Share your contact information
Update time
We have emailed NewLife Pharmacy to request guidance on next steps. We plan to meet with their team on Monday morning, October 19.
We will also ask why Fifty 410 is only now learning about the voluntary recall and why our team did not receive a direct notification.
We will share confirmed information and next steps on this page as soon as they are available. Thank you for your patience as we work to get answers.
Fifty 410 Team
Update time
Apothecary Pharma has initiated a voluntary Class II recall involving certain lots of tirzepatide. The FDA lists the reason for the recall as a “Lack of Assurance of Sterility.”
We have already reached out to the dispensing pharmacy (NewLife) to request a list of potentially affected patients, confirm which lots were distributed, and better understand the appropriate next steps.
At this time, we are still gathering information and working to determine which, if any, Fifty 410 patients may be impacted.
We understand that reports like this can be concerning. While this is a voluntary recall, we take any concerns involving medication safety seriously and want to make sure we have accurate information before communicating a resolution.
Please allow us some time to gather the facts, work with the dispensing pharmacy, and put together a clear plan of action. We are moving as quickly as possible and will provide updates as soon as we have confirmed information.
We appreciate your patience and understanding as we work through this.
Fifty 410 Team
We will provide more information on this page as it becomes available.
Compare the medication, strength, vial size, lot number, and beyond-use date with the FDA information below.
Look up a lot numberIf your label matches, or you’re unsure, contact NewLife Pharmacy or your prescriber for medication-specific guidance.
NewLife contact detailsFollow any instructions from Apothecary Pharma, your dispensing pharmacy, or FDA. Check this page for further Fifty 410 updates.
FDA patient guidanceLook for “LOT” on the vial or its packaging. Select the medication and enter the complete lot number.
This checks the FDA lot list shown on this page. It does not verify your individual prescription or confirm which patients received an affected vial.
Your entry is checked on your device and is not submitted to Fifty 410.
If you have confirmed that your medication is included in this recall, share your contact information so the Fifty 410 team can follow up.
Four short questions, then a review before you submit.
We collect these details for recall-related follow-up. Please do not include additional medical information.
The Fifty 410 team has your contact details for recall-related follow-up.
Your reference:
Please keep this reference for your records.
The FDA record lists two products from Apothecary Pharma LLC. Our statement above addresses the tirzepatide recall; the same FDA event also lists the NAD+ product shown here.
18 mg/mL · 4 mL sterile multidose vial
| Lot number | Beyond-use date (BUD) |
|---|---|
| AP-202622 | |
| AP-202623 | |
| AP-202624 | |
| AP-202625 | |
| AP-202627 | |
| AP-202628 | |
| AP-202629 | |
| AP-202630 | |
| AP-202631 | |
| AP-202632 | |
| AP-202633 | |
| AP-202634 | |
| AP-202635 | |
| AP-202636 | |
| AP-202637 | |
| AP-202638 | |
| AP-202639 | |
| AP-202640 | |
| AP-202641 | |
| AP-202642 | |
| AP-202643 | |
| AP-202644 |
200 mg/mL · 6 mL sterile multidose vial
| Lot number | Beyond-use date (BUD) |
|---|---|
| AP-202647 |
BUD means beyond-use date. All lots listed in the FDA event are included here, including those with past BUDs. Information reviewed . Check the FDA record for the latest recall details.
For help identifying your vial or questions about medication dispensed by NewLife, contact their team.